Key variants like GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 influence how your body responds to semaglutide and predispose you to specific metabolic patterns
New data showed that seven out of the 403 participants who received retatrutide experienced arrhythmias (irregular heartbeats), and three treated participants experienced major cardiovascular complications, compared with none in the placebo group
With known benefits on metabolic health and possible direct effects on vascular function, GLP-1 agonists could help manage walking limitations in patients with PAD
Tier 3 patients often experience significant improvements in energy levels and brain fog within 2-4 weeks, with substantial weight loss and metabolic improvements within 8-12 weeks, and continued progress over 6-12 months
It is important to note that weight loss outcomes may vary between individuals and depend on various factors such as adherence to treatment, lifestyle modifications, and overall health
People just starting to lose weight, supplementing a GLP-1 prescription, or transitioning off medications can use resM
